10.1021/tx00034a019 67 PicottiP.AebersoldR
Drokhlyansky et al., 2020)
We are hopeful about the potential to bring a first-of-its-kind treatment option to people living with moderate-to-severe OSA and obesity, who currently have no pharmaceutical treatments for the underlying disease, says a spokesperson for Eli Lilly
Written by Lauren Lund, APRN-CNP Reviewed by Laurianne Scott, DO LAST UPDATED: Nov 11, 2024 | 8 min read If you are taking weight loss medications, such as GLP-1 receptor agonists (semaglutide or tirzepatide), you might be experiencing some unwanted side effects, one of the most common being constipation
Beyond hepatic manifestations, MASLD is intrinsically linked to systemic metabolic disorder
Due to its action on the central nervous system, tesofensine should be used cautiously, especially by individuals with pre-existing cardiovascular conditions